SBC-102, which is under clinical trials, is a recombinant human lysosomal acid lipase enzyme responsible for the breakdown of cholesteryl esters and triglycerides.
Synageva R&D CMO and head Anthony Quinn said the fast track program is designed to facilitate drug development and expedite the review of drugs to treat serious diseases like LAL Deficiency.
"We look forward to work closely with the FDA as we complete clinical development to facilitate regulatory review and accelerate the delivery of a treatment for patients suffering from this devastating disease," Quinn said.